Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are rising more than 20% Tuesday morning at $3.89.
Longeveron today reported long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).
The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.
LGVN has traded in the range of $2.50 – 9.34 in the last 1 year.
Source: Read Full Article
Lates News:
-
Affirm Shares Ascend Following Deal With Walmart
-
US Presidential Candidate Pledges Dollar Backing With Bitcoin, No Bitcoin Capital Gains Tax
-
Snapshot Of World Markets
-
Bowlero Corp. Slips 8% Following Q1 Results
-
Standard Chartered Sees Bitcoin Breaking 2024 With A Mind-Blowing BTC Moonshot To $100,000 Price